Company InfoNewsInvestor InformationResearchDevelopmentCareersBusiness DevelopmentResourcesDrugs databaseBack to the home pageSearch  
Drugs database
Drugs A-Z

Brands A-Z

Drugs by categories

Drugs by manufacturer

Drugs by packager

Antibiotics for sale

Online Viagra bestellen in Nederland

Home / Drugs / Starting with A / Adalimumab 		 
Adalimumab
  

Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.
BrandsHumira
Humira (Abbott Laboratories)
Humira Pen
CategoriesAntirheumatic Agents
Immunomodulatory Agents
PackagersAbbott Laboratories Ltd.
Vetter Pharma Fertigung GmbH and Co. KG
SynonymsIg gamma-1 chain C region

indication

For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.

pharmacology

Used in the treatment of immune system mediated diseases, adalimumab binds specifically to TNF-alpha and blocks its general cytokine effects, thereby reducing TNF-induced inflammation and halting tissue destruction.

mechanism of action

Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement.

biotransformation

Most likely removed by opsonization via the reticuloendothelial system.

half life

10-20 days.

Terms of Use